A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome

Clinical Neuropharmacology

Volumn 35, Issue 4, 2012, Pages 165-173

  Lal, Ritu ^a   Ellenbogen, Aaron ^b   Chen, Dan ^a   Zomorodi, Katie ^a   Atluri, Harisha ^a   Luo, Wendy ^a   Tovera, James ^a   Hurt, Janet ^c   Bonzo, Daniel ^a   Lassauzet, Marie Liesse ^a   Vu, Amanda ^d   Cundy, Kenneth C ^a  

^a XenoPort Inc   (United States)

^b Quest Research Institute   (United States)

^c PHARMACYCLICS INC   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

dose proportionality; gabapentin enacarbil; restless legs syndrome

Indexed keywords

GABAPENTIN ENACARBIL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AFFECT; CARBAMATES; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 84863981175     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318259eac8     Document Type: Article

References (29)

1. RLS Foundation Web Site. Available at: http://www.rls.org/namechange. Accessed July 5, 2011.
2. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119. (Pubitemid 36527231)
3. Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007;120:S22-S27. (Pubitemid 46014146)
4. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-922. (Pubitemid 38879959)
5. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled trial of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-446.
6. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-168.
7. Horizant US [prescribing information]. Available at: http://us.gsk.com/ products/assets/us-horizant.pdf. Accessed August 7, 2011.
8. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(T)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311:324-333. (Pubitemid 39287812)
9. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(T)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311:315-323. (Pubitemid 39287811)
10. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378-1388.
11. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-281. (Pubitemid 23041744)
12. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998;31:91-99. (Pubitemid 28361756)
13. Gidal BE, Radulovic LL, Kruger S, et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40:123-127. (Pubitemid 30339403)
14. Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol 2012; Epub 15 Mar: doi:10.1177/0091270012439209 [Epub ahead of print].
15. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132. (Pubitemid 36527232)
16. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003;4:95-97. (Pubitemid 36527229)
17. Guy W. Clinical global impressions (CGI). In: Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare, National Institute of Mental Health, Psychopharmacology Research Branch; 1976:217-222.
18. Curran SL, Andrykowski MA, Studts JL. Short form of the Profile of Mood States: psychometric information. Psychology Assessment 1995;7:80-83.
19. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283-297. (Pubitemid 38526150)
20. Keefe RS, Poe M, Walker TM, et al. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 2006;163:426-432. (Pubitemid 44469384)
21. Cornblatt BA, Risch NJ, Faris G, et al. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 1988;26:223-238.
22. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005;4:465-475. (Pubitemid 40982457)
23. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
24. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376-381.
25. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, two-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311-320.
26. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579. (Pubitemid 35387065)
27. Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol 2010;69:498-507.
28. Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009;31:1776-1786.
29. Neurontin US Physician Prescribing Information. Available at: http://www.pfizer.com/files/products/uspi-neurontin.pdf. Accessed July 10, 2011.